(Q36744991)

16 August 2017

1 reference

title

Should a new tuberculosis vaccine be administered intranasally? (English)

1 reference

16 August 2017

0 references

1 reference

16 August 2017

1 reference

16 August 2017

Per Brandtzaeg

1 reference

16 August 2017

Stefan Svenson

series ordinal

1 reference

16 August 2017

publication date

26 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

257-266

1 reference

Global incidence of multidrug-resistant tuberculosis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

A historical and molecular phylogeny of BCG strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The role of BCG in prevention of leprosy: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Progress in tuberculosis vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Vaccine visions and their global impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Role of secretory antibodies in the defence against infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Strategies for designing and optimizing new generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Let's go mucosal: communication on slippery ground

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

History of oral tolerance and mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Strategies for designing vaccines eliciting Th1 responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Towards the rational design of Th1 adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Cytokines as adjuvants for the induction of mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Molecular adjuvants for mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mucosal immunisation: adjuvants and delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Recent findings in immunology give tuberculosis vaccines a new boost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Protective role of γ/δ T cells and α/β T cells in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guérin vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

BCG-induced mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Nasal boost with adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced protection in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Improved tuberculosis DNA vaccines by formulation in cationic lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mucosal tolerance and immunity: regulating the development of allergic disease and asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The lung cytokine microenvironment influences molecular events in the lymph nodes during Th1 and Th2 respiratory mucosal sensitization to antigen in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Intranasal vaccination of mice against infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Is the development of a new tuberculosis vaccine possible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

BCG vaccine: efficacy and indications for vaccination and revaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Design of the Brazilian BCG-REVAC trial against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Boosting vaccine for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Advances in tuberculosis vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Prime-boost immunisation strategies for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Recent advances in mucosal vaccines and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Induction of secretory immunity and memory at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Vaccine delivery--current trends and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Noninvasive delivery technologies: respiratory delivery of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Bi-directional nasal delivery of aerosols can prevent lung deposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Effects of systemic and local immunization on alveolar epithelial permeability to protein in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Increase in gamma interferon-secreting CD8(+), as well as CD4(+), T cells in lungs following aerosol infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.12.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2006.12.006

1 reference

16 August 2017

1 reference